CAP TODAY/AstraZeneca Webinar: Why test for HRR deficiency? A new pathway in pancreatic and prostate cancer

Thank you

This live web event has ended. Thank you for attending.

Description

Why test for HRR deficiency?
A new pathway in pancreatic
and prostate cancer

Why should you register now for this webinar?

Understand the molecular biology of the HRR pathway and its
relation to carcinogenesis
Explore the role of PARP inhibition in cancers with HRD
Understand the rationale and methodology for BRCA and HRD testing
Discuss testing and identification of patients with HRD pancreatic
and prostate cancer

Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenters: Zin Htway, PhD, MBA, and Leigha Senter-Jamieson, MS, LGC
You will have the opportunity to ask questions of our distinguished presenters.

CAP TODAY does not endorse any of the products or services named within. ©2019 AstraZeneca. All rights reserved.

Contributors

Bob McGonnagle

Publisher, CAP TODAY
Zin Htway, PhD, MBA

Supervisor, Anatomic Pathology Department
Hospital Hazardous Materials Management Safety Officer
Laboratory Team Leader: Emerging Infectious Diseases
Research Oversight Committee:
Administrative Chair of Committee
Los Robles Hospital and Medical Center
Thousand Oaks, CA
Leigha Senter-Jamieson, MS, LGC

Associate Director, Genetic Counseling Graduate Program
Associate Professor, Division of Human Genetics
The Ohio State University
Columbus, OH